Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952211 | 0.86 | NLRP3 (0.67) | NLRP3THRBTP53KCNH2 | |
| SCHEMBL23952602 | 0.81 | NLRP3 (0.47) | NLRP3 | |
| SCHEMBL23950385 | 0.79 | NLRP3 (0.61) | NLRP3THRBTP53KCNH2 | |
| SCHEMBL25816790 | 0.76 | NLRP3 (0.45) | NLRP3TP53 | |
| SCHEMBL23952067 | 0.75 | NLRP3 (0.54) | NLRP3THRBTP53KCNH2 | |
| SCHEMBL23952207 | 0.75 | NLRP3 (0.75) | NLRP3TP53 | |
| SCHEMBL25815490 | 0.75 | GAA (0.54) | NLRP3 | |
| SCHEMBL21632361 | 0.73 | NLRP3 (1.00) | NLRP3TP53KCNH2 | |
| SCHEMBL25633373 | 0.73 | THRB (0.76) | NLRP3THRBTP53KCNH2 | |
| SCHEMBL25634247 | 0.72 | THRB (0.65) | NLRP3THRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| WO-2021209539-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885THRB 2843/4885GRIN2B 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.